Transport and elimination of recombinant human NGF during long-term delivery to the brain

Brain Research

Volumn 727, Issue 1-2, 1996, Pages 169-181

  Krewson, Christine E ^a   Saltzman, W Mark ^a  

^a Johns Hopkins University   (United States)

Author keywords

Brain interstitium; Controlled release; Diffusion; Elimination; Polymer; Recombinant human nerve growth factor

Indexed keywords

POLYMER; RECOMBINANT NERVE GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; INTRACEREBRAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 0030586332     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00378-2     Document Type: Article

References (73)

1. [1] Appel, S.H., A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease, Ann. Neurol., 10 (1981) 499-505.
2. [2] Barnett, J., Baecker, P., Routledge-Ward, C. et al., Human β nerve growth factor obtained from a baculovirus expression system has potent in vitro and in vivo neurotrophic activity, Exp. Neurol., 110 (1990) 11-24.
3. [3] Bartus, R.T., Dean, R.L., Beer, B. et al., The cholinergic hypothesis of geriatric memory dysfunction, Science, 217 (1982) 408-417.
4. [4] Beaty, C.E. and Saltzman, W.M., Controlled growth factor delivery induces differential neurite outgrowth in three-dimensional cell cultures. J. Control. Release, 24 (1993) 15-23.
5. [5] Bickel, U., Yoshikawa, T., Landaw, E.M. et al., Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery, Proc. Natl. Acad. Sci. USA, 90 (1993) 2618-2622.
6. [6] Bruce, G. and Heinrich, G., Production and characterization of biologically active recombinant human nerve growth factor, Neurobiol. Aging, 10 (1989) 89-94.
7. [7] Burton, L.E., Schmelzer, C.H., Szonyi, E. et al., Activity and biospecificity of proteolyzed forms and dimeric combinations of recombinant human and murine nerve growth factor, J. Neurochem., 59 (1992) 1937-1945.
8. [8] Buxser, S., Vroegop, S., Decker, D. et al., Single-step purification and biological activity of human nerve growth factor produced from insect cells, J. Neurochem., 56 (1991) 347-351.
9. [9] Camarata, P.J., Suryanarayanan, R. and Turner, D.A., Sustained release of nerve growth factor from biodegradable polymer microspheres, Neurosurgery, 30 (1992) 313-319.
10. [10] Chapman, C.A., Banks, B.E.C, Vernon, C.A. et al., The isolation and characterization of nerve growth factor from the prostate gland of the guinea-pig, Eur. J. Biochem., 115 (1981) 347-351.
11. [11] Chen, K.S. and Gage, F.H., Somatic gene transfer of NGF to the aged brain: Behavioral and morphological amelioration, J. Neurosci., 15 (1995) 2819-2825.
12. 125l]nerve growth factor by cholinergic neurons and down-regulated trkA expression in the medal septum of aged rats, Neuroscience, 62 (1994) 625-629.
13. [13] Coyle, J.T., Price, D.L. and DeLong, M.R., Alzheimer's disease: A disorder of cortical cholinergic innervation, Science, 219 (1983) 1184-1190.
14. [14] Crutcher, K.A., Scott, S.A., Liang, S. et al., Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease, J. Neurosci., 13 (1993) 2540-2550.
15. [15] Curran, R.E., Mosher, M.B., Owens, E.S. et al., Cerebrospinal fluid production rates determined by simultaneous albumin and inulin perfusion. Exp. Neurol., 29 (1970) 546-553.
16. [16] Davies, P., Is it possible to design rational treatment for the symptoms of Alzheimer's disease?, Drug Dev. Res., 5 (1985) 69-75.
17. [17] Davis, K.L., Thal, L.J., Elkan, R.G. et al., A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer's disease, N. Engl. J. Med., 327 (1992) 1253-1259.
18. [18] Emerich, D.F., Winn, S.R., Harper, J. et al., Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons, J. Comp. Neurol., 349 (1994) 148-164.
19. [19] Ferguson, I.A., Schweitzer, J.B., Bartlett, P.F. et al., Receptor-mediated retrograde transport in CNS neurons after intraventricular administration of NGF and growth factors, J. Comp. Neurol., 313 (1991) 680-692.
20. [20] Fischer, W., Wictorin, K., Bjorklund, A. et al., Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor, Nature, 329 (1987) 65-68.
21. [21] Friden, P.M., Walus, L.R., Watson, P. et al., Blood-brain barrier penetration and in vivo activity of an NGF conjugate, Science, 259 (1993) 373-377.
22. [22] Gage, F., Armstrong, D., Williams, L. et al., Morphological response of axotomized septal neurons to nerve growth factor, J. Comp. Neurol., 269 (1988) 147-155.
23. [23] Gannushkina, I.V., Sukhorukova, L.I. and Baranchikova, M.V., Dependence of traumatic brain edema on immunologic reactivity against tissue antigens. In H.M. Pappius and W. Feindel (Eds.), Dynamics of Brain Edema, Springer-Verlag, New York, 1976, pp. 155-160.
24. [24] Goldstein, L.D., Reynolds, C.P. and Perez-Polo, J.R., Isolation of human nerve growth factor from placental tissue, Neurochem. Res., 3 (1978) 175-183.
25. [25] Gregoriadis, G., The carrier potential of liposomes in biology and medicine, N. Engl. J. Med., 295 (1976) 704-710.
26. [26] Harper, G.P., Glanville, R.W. and Thoenen, H., The purification of nerve growth factor from bovine seminal plasma, J. Biol. Chem., 257 (1982) 8541-8548.
27. [27] Harper, G.P. and Thoenen, H., The distribution of nerve growth factor in the male sex organs of mammals. J. Neurochem., 34 (1980) 893-903.
28. [28] Hartikka, J. and Hefti, F., Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro. J. Neurosci. Res., 21 (1988) 352-364.
29. [29] Hefti, F., Dravid, A. and Hartikka, J., Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions, Brain Res., 293 (1984) 305-311.
30. [30] Hefti, F., Hartikka, J., Eckenstein, F. et al., Nerve growth factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons, Neuroscience. 14 (1985) 55-68.
31. [31] Hefti, F., Hartikka, J. and Knusel, B., Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases, Neurobiol. Aging, 10 (1989) 515-533.
32. [32] Hefti, F. and Mash, D., Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's Disease, Neurobiol. Aging, 10 (1989) 75-87.
33. [33] Hefti, F. and Weiner, W.J., Nerve growth factor and Alzheimer's disease. Ann. Neurol., 20 (1986) 275-281.
34. [34] Heisey, S.R., Brain and choroid plexus blood volumes in vertebrates, Comp. Biochem. Physiol., 26 (1968) 489-498.
35. [35] Higgins, G.A., Koh, S., Chen, K.S. et al., NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat, Neuron, 3 (1989) 247-256.
36. [36] Hoffman, D., Wahlberg, L. and Aebischer, P., NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion, Exp. Neurol., 110 (1990) 39-44.
37. [37] Hogue-Angeletti, R.A. and Bradshaw, R.A., Nerve growth factor in snake venoms. In C.-Y. Lee (Eds.), Handbook of Experimental Pharmacology, Springer-Verlag, Berlin, 1979, pp. 276-294.
38. [38] Iwane, M., Kitamura, Y., Kaisho, Y. et al., Production, purification and characterization of biologically active recommbinant human nerve growth factor, Biochem. Biophys. Res. Commun., 171 (1990) 116-122.
39. [39] Jetté, N., Cole, M.S. and Fahnestock, M., NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients, Mol. Brain Res., 25 (1994) 242-250.
40. [40] Johns, C.A., Haroutunian, V., Greenwald, B.S. et al., Development of cholinergic drugs for the treatment of Alzheimer's disease, Drug Dev. Res., 5 (1985) 77-96.
41. [41] Kanaya, E., Higashizaki, T., Ozawa, F. et al., Synthesis and secretion of nerve growth factor by Saccharomyces cerevisiae, Gene, 83 (1989) 65-74.
42. [42] Knusel, B., Burton, L., Longo, F. et al., Trophic actions of recombinant human nerve growth factor on cultured rat embryonic CNS cells, Exp. Neurol., 110 (1990) 274-283.
43. [43] Koliatsos, V., Applegate, M., Knusel, B. et al., Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat, Exp. Neurol., 112 (1991) 161-173.
44. [44] Koliatsos, V.E., Clatterbuck, B.S., Nauta, G.J.W. et al., Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates, Ann. Neurol., 30 (1991) 831-840.
45. [45] Kordower, J.H., Winn, S.R., Liu, Y.-T. et al., The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor, Proc. Natl. Acad. Sci. USA, 91 (1994) 10898-10902.
46. [46] Krewson, C.E., Klarman, M.L. and Saltzman, W.M., Distribution of nerve growth factor following direct delivery to brain interstitium, Brain Res., 680 (1995) 196-206.
47. [47] Krewson, C.E. and Saltzman, W.M., Targetting of peptides and proteins in the brain following release from implantable polymers. In V.H.L. Lee, M. Hasida and Y. Mizushima (Eds.), Trends and Future Perspectives in Peptide and Protein Drug Delivery, Harwood Academic Publishers, London, 1995, pp. 273-294.
48. 125l]nerve growth factor in the rat brain following a single intraventricular injection: Correlation with the topographical distribution of trkA messenger RNA-expressing cells, Neuroscience, 54 (1993) 445-460.
49. [49] Lieberman, D.M., Laske, D.W., Morrison, P.F. et al., Convection-enhanced distribution of large molecules in gray matter during interstitial infusion, J. Neurosurg., 82 (1995) 1021-1029.
50. [50] Montero, C.N. and Hefti, F., Rescue of lesioned septal cholinergic neurons by nerve growth factor: Specificity and requirement for chronic treatment, J. Neurosci., 8 (1988) 2986-2999.
51. [51] Morse, J.K., Wiegand, S.J., Anderson, K. et al., Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection, J. Neurosci., 13 (1993) 4146-4156.
52. [52] Mufson, E.J., Conner, J.M. and Kordower, J.H., Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis, Neuroreport, 6 (1995) 1063-1066.
53. [53] Murase, K., Nabeshima, T., Robitaille, Y. et al., NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease, Biochem. Biophys. Res. Comm., 193 (1993) 198-203.
54. [54] Pardridge, W.M., Peptide Drug Delivery to the Brain, Raven Press, New York, 1991, 357 pp.
55. [55] Patlak, C. and Fenstermacher, J., Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion, Am. J. Physiol., 229 (1975) 877-884.
56. [56] Phelps, C., Gage, F., Growdon, J. et al., Potential use of nerve growth factor to treat Alzheimer's disease, Neurobiol. Aging, 10 (1989) 205-207.
57. [57] Poduslo, J.F., Curran, G.L. and Berg. C.T., Macromolecular permeability across the blood-nerve and blood-brain barriers, Proc. Natl. Acad. Sci. USA, 91 (1994) 5705-5709.
58. [58] Powell, E.M., Sobarzo, M.R. and Saltzman, W.M., Controlled release of nerve growth factor from a polymeric implant, Brain Res., 515 (1990) 309-311.
59. [59] Reulen, H.J., Graham, R., Fenske, M. et al., The role of tissue penetration and bulk flow in the formation and resolution of cold-induced edema. In H.M. Pappius and W. Feindel (Eds.), Dynamics of Brain Edema, Springer-Verlag, New York, 1976, pp. 103-112.
60. [60] Reulen, H.J., Graham, R., Spatz, M. et al., Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema, J. Neurosurg., 46 (1977) 24-35.
61. [61] Reulen, H.J., Tsuyumu, M., Tack, A. et al., Clearance of edema fluid into cerebrospinal fluid, J. Neurosurg., 48 (1978) 754-764.
62. [62] Rosenberg, G., Kyner, W. and Estrada, E., Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions, Am. J. Physiol., 238 (1980) F42-F49.
63. [63] Salehi-Had, S. and Saltzman, W.M., Controlled intracranial delivery of antibodies in the rat. In J. Cleland and R. Langer (Eds.), Formulation and Delivery of Proteins and Peptides, American Chemical Society, Washington, DC, 1994, pp. 278-291.
64. [64] Saltzman, W.M. and Radomsky, M.L., Drugs released from polymers: Diffusion and elimination in brain tissue, Chem. Engin. Sci., 46 (1991) 2429-2444.
65. [65] Schmelzer, C.H., Burton, L.E., Chan, W.-P. et al., Biochemical characterization of recombinant human nerve growth factor, J. Neurochem., 59 (1992) 1675-1683.
66. [66] Seiker, Å., Nordberg, A., von Holst, H. et al., Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy, Behav. Brain Res., 57 (1993) 255-261.
67. [67] Simpkins, J., Bodor, N. and Enz, A., Direct evidence for brain-specific release of dopamine from a redox delivery system, J. Pharmaceut. Sci., 74 (1985) 1033-1036.
68. [68] Tokuda, H., Takakura, Y. and Hashida, M., Targeted delivery of polyanions to the brain, Proc. Intern. Symp. Control Rel. Bioact. Mat. 20 (1993) 270-271.
69. [69] Tuszynski, M.H. and Gage, F.H., Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery, Proc. Natl. Acad. Sci. USA, 92 (1995) 4621-4625.
70. [70] Ullrich, A., Gray, A., Berman, C. et al., Human β-nerve growth factor gene sequence highly homologous to that of mouse, Nature, 303 (1983) 821-825.
71. [71] Williams, L., Varon, S., Peterson, G. et al., Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection, Proc Natl Acad Sci USA, 83 (1986) 9231-9235.
72. [72] Winn, S.R., Hammang, J.P., Emerich, D.F. et al., Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the suvival of axotomized septal cholinergic neurons, Proc Natl Acad Sci USA, 91 (1994) 2324-2328.
73. [73] Yamada, S., DePasquale, M., Patlak, C.S. et al., Albumin outflow into deep cervical lymph from different regions of rabbit brain, American Journal of Physiology, 240 (1991) F329-F336.